Bronchiectasis is a long-term condition when your body produces a lot of phlegm after experiencing lung damage ...

Early signs of illnesses can often show up in unexpected places. Being able to identify them can help you get proper and ...

Bronchiectasis, a lesser-known condition that damages the lungs and airways, often has no clear cause and is incurable. The ...

This condition causes your fingertips to swell, creating a more rounded or clubbed look around the fingernails. Clubbing ...

BRONCHIECTASIS is protean in its expressions as it is sometimes obscure in its origin. The clinical picture varies in individual patients, but common to the severer cases is a history of harassing ...

Panelists discuss how bronchiectasis is more common than previously thought, with growing awareness, research, and specialized centers improving diagnosis and treatment options, though challenges ...

Panelists discuss how future bronchiectasis research will focus on precision medicine, identify treatable traits, and expand networks of Centers of Excellence to provide advanced care and clinical ...

Health registries have become an increasingly powerful tool to document outcomes for particular populations, and are usually grouped around a single disease, procedure, or medication.1 Although health ...

Neutrophils are the core airway inflammatory cell in bronchiectasis. The drug appeared safe, although with a somewhat higher incidence of hyperkeratosis. Targeting airway inflammation with ...

Bronchiectasis impacts up to 500,000 Americans, but there is often misdiagnosis or delayed diagnosis as the condition can present similarly to other pulmonary conditions such as COPD or asthma.

Dublin, Dec. 09, 2024 (GLOBE NEWSWIRE) -- The "Bronchiectasis - Market Insight, Epidemiology and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. This report ...

A Prescription Drug User Fee Act target date of August 12, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...